When contaminated steroid injections from the New England Compounding Center, in Massachusetts, infected more than 750 people and caused 64 deaths in 2012, many hospitals took a hard look at boosting their in-house production of compounded sterile products (CSPs). But some forward-looking health systems had already started down that path, seeking to exert greater control over the safety and cost of their drug supplies.
Brigham and Women’s Hospital (BWH), in Boston, had begun expanding its